{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:56:02Z","timestamp":1780516562486,"version":"3.54.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.xphs.2023.01.018","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T02:51:31Z","timestamp":1674701491000},"page":"1733-1739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preliminary Evaluation of Stability Data for Dolutegravir-Containing Triple Active Formulations Intended for PEPFAR. Degradation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide as the Limiting Factor"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6828-2209","authenticated-orcid":false,"given":"George","family":"Lunn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2023.01.018_bib0001","first-page":"Article 4","article-title":"Making PEPFAR: a triumph of medical diplomacy","volume":"2","author":"Varmus","year":"2013","journal-title":"Sci Diplomacy"},{"key":"10.1016\/j.xphs.2023.01.018_bib0002","unstructured":"The United States President's Emergency Plan for AIDS Relief 2021 Annual Report to Congress. Available at: https:\/\/www.state.gov\/wp-content\/uploads\/2021\/02\/PEPFAR2021AnnualReporttoCongress.pdf); Accessed 25 December 2022."},{"key":"10.1016\/j.xphs.2023.01.018_bib0003","unstructured":"Quincot G., Azenha M., Barros J., Faria R. Use of salt solutions for assuring constant relative humidity conditions in contained environments. https:\/\/studylib.net\/doc\/18269015\/use-of-salt-solutions-for-assuring-constant-relative-humi. Accessed 25 December 2022."},{"key":"10.1016\/j.xphs.2023.01.018_bib0004","unstructured":"Quick Reference Guide for PEPFAR Database. Available at: https:\/\/www.fda.gov\/international-programs\/presidents-emergency-plan-aids-relief-pepfar\/quick-reference-guide-pepfar-database. Accessed 25 December 2022."},{"key":"10.1016\/j.xphs.2023.01.018_bib0005","unstructured":"Orange Book: approved Drug Products with Therapeutic Equivalence Evaluations. Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/default.cfm. Accessed 25 December 2022."},{"key":"10.1016\/j.xphs.2023.01.018_bib0006","unstructured":"WHO recommends dolutegravir as preferred HIV treatment option in all populations. Available at: WHO recommends dolutegravir as preferred HIV treatment option in all populations. Accessed 25 December 2022."},{"key":"10.1016\/j.xphs.2023.01.018_bib0007","unstructured":"Tenofovir, Lamivudine, and Dolutegravir (TLD) Transition. General Information for Clients, Clinicians, Counselors, and other Service Providers (August 2019). Available at: fhi360.org\/sites\/default\/files\/media\/documents\/linkages-tld-transition-information.pdf. Accessed 25 December 2022."},{"key":"10.1016\/j.xphs.2023.01.018_bib0008","unstructured":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240031593 (pp. 131 and 174). Accessed 25 December 2022."},{"key":"10.1016\/j.xphs.2023.01.018_bib0009","unstructured":"Two times a year is better than four: people spend less time off ART if they only visit their clinic every six months, African study shows. Available at: https:\/\/www.aidsmap.com\/news\/may-2021\/two-times-year-better-four-people-spend-less-time-art-if-they-only-visit-their-clinic. Accessed 25 December 2022."},{"issue":"12","key":"10.1016\/j.xphs.2023.01.018_bib0010","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/jssc.201000039","article-title":"Development of a validated liquid chromatographic method for the determination of related substances and assay of tenofovir disoproxil fumarate","volume":"33","author":"Ashenafi","year":"2010","journal-title":"J Sep Sci"},{"key":"10.1016\/j.xphs.2023.01.018_bib0011","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpba.2016.08.022","article-title":"Stability behaviour of antiretroviral drugs and their combinations. 4: characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate","volume":"131","author":"Golla","year":"2016","journal-title":"J Pharm Biomed Anal"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:44:15Z","timestamp":1758361455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354923000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0022354923000205"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.01.018","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preliminary Evaluation of Stability Data for Dolutegravir-Containing Triple Active Formulations Intended for PEPFAR. Degradation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide as the Limiting Factor","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}